TIL Therapies Summit 2023

The first commercial TIL therapy is brewing at Iovance, along with various clinical readouts which are set to come to fruition in 2023, along with the 5th TIL Therapies Summit which returns as the only forum to address bottlenecks in end-to-end TIL development from discovery now through to commercialization.

Unite with TIL experts across industry and academia as pioneers from Iovance Biotherapeutics, Turnstone Biologics, Achilles Therapeutics and Lyell Immunopharma share clinical updates, next-gen engineering, and novel innovations to reduce cost and turnaround time to turbocharge preclinical and clinical development of safe, scalable and effective TIL therapies.

With 23+ TIL expert speakers, 75% of which new, 8 new companies and a brand-new Manufacturing and Characterization Bootcamp, you won't want to miss this unrivalled opportunity to connect and collaborate with this niche community to secure clinical validation, turbocharge modified therapies and accelerate the next wave of TIL therapies into the clinic and beyond.

URLs:
Website: https://go.evvnt.com/1759726-0?pid=10018
Tickets: https://go.evvnt.com/1759726-2?pid=10018
Brochure: https://go.evvnt.com/1759726-3?pid=10018

Prices:
Drug Developer - Conference + Bootcamp Day: USD 4622.00,
Drug Developer - Conference + Workshop Day: USD 4297.00,
Drug Developer - Conference Only: USD 2999.00,
Academic - Conference + Bootcamp Day: USD 3972.00,
Academic - Conference + Workshop Day: USD 3697.00,
Academic - Conference Only: USD 2599.00,
Service Provider - Conference + Bootcamp Day: USD 4047.00,
Service Provider - Conference + Workshop Day: USD 5297.00,
Service Provider - Conference Only: USD 3799.00

Speakers: Adam Schoenfeld, Medical Oncologist, Memorial Sloan Kettering Cancer Center, Allison Betof, Warner Director, Solid Tumor Cellular Therapy and Melanoma Medical Oncology Program, Stanford University, Andrew Weinberg, Chief Scientific Officer and President, AgonOx, Barbara Sennino, Vice President, Immunotherapy, Turnstone Biologics, Cara Haymaker, Assistant Professor, MD Anderson Cancer Center, Dipen Sangurdekar, VP and Head, Data Sciences, KSQ Therapeutics, Eduardo Davila, Co-Founder and Chief Scientific Officer, Trampoline Pharma, Ena Wang, Vice President, Cell Therapy, Nurix Therapeutics, Eric Chen, Founder and Chief Excecutive Officer, Achelois Biopharma, Friedrich Graf Finckenstein, Chief Medical Officer, Iovance Biotherapeutics, George Coukos, Branch Director, Ludwig Institute for Cancer Research, Georgia Fodelianaki, Global Product Manager, Immunotherapy, Miltenyi Biotec, Hua Liu, CSO, Shanghai Xinghua Biomedical and Biopharmaceuticals, Jingwei Sun, Director, Early Discovery, Grit Biotechnology, Madan Jagasia, Chief Executive Officer, Obsidian Therapeutics, Mario Kuttke, Head of Cell Therapy, invIOs, Melissa DeFrancesco, Director, Head of Process Development, Lyell Immunopharma, Michael Lotze, Professor of Surgery, Immunology and Bioengineering, Pittsburgh University, Parameswaran Hari, Chief Development Officer, Obsidian Therapeutics, Rafael Cubas, Senior Director - Research, Iovance Biotherapeutics, Sergio Quezada, Chief Scientific Officer, Achilles Therapeutics, Simón Vidal, Head of T Cell Therapeutics, Retro Biosciences, Stewart Abbot, Chief Scientific Officer, Turnstone Biologics, Suman Kumar Vodnala, Senior Director, Early T-Cell Product Discovery, Lyell Immunopharma, Sumit Verma, Vice President, Global Strategic Manufacturing, Iovance, Ulrik Cordes, Chief Executive Officer and President, Cbio